Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells, shows a study published today in eLife.
The findings may lead to new ways to diagnose, treat or prevent rare blood cancers and to identify patients who could go on to develop a second type of blood cancer.
Peripheral T cell lymphoma (PTCL) and angioimmunoblastic T cell lymphoma (AITL) are two uncommon types of cancers that affect immune T cells. “AITL can be very aggressive, with only about one-third of patients surviving at least five years after their diagnosis,” explains first author Shuhua Cheng, Senior Research Associate at the Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, US. “To develop more effective therapies against AITL and PTCL, we need to learn more about what causes them.”
Cheng and the team used next-generation genome sequencing to analyse 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumours and to secondary cancers in some patients. They found that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumours. These mutations in the precursor cells have been thought to be related to aging.
In addition, the team found that the mutations associated with the progression of these tumours might be linked to smoking or exposure to second-hand smoke. This suggests that the cessation of smoking or avoiding exposure to second-hand smoke may have beneficial effects in preventing the development of these T-cell tumours. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumours were at higher risk of developing additional types of tumours.
“Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers,” says senior author Wayne Tam, Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. “The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumours, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Cancer Biology and Medicine, while exploring creative new ways to improve how research is assessed and published. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Cancer Biology research published in eLife, visit https://elifesciences.org/subjects/cancer-biology.
And for the latest in Medicine, see https://elifesciences.org/subjects/medicine.